Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea
Pneumococcal disease poses a substantial clinical and economic burden, especially among children under 5 years old. The 13-valent pneumococcal conjugate vaccine (PCV13) was first introduced in South Korea’s Childhood Immunization Program in 2014. In October 2023, the Ministry of Food and Drug Safety...
Saved in:
| Main Authors: | Young June Choe, Yunjin Jeon, Jihyun Park, Hyesun Kim, Gyongseon Yang, Salini Mohanty, Lefteris Floros, Min Huang, Nitika Chhabra, Shalini Kumari, Jasmeet Singh, Isaya Sukarom |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2025.2515650 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A population-based study on the burden of hospitalized pediatric pneumococcal disease in Taiwan before and after the introduction of 13-valent pneumococcal conjugate vaccine into the childhood immunization program in 2015
by: Ting-An Yen, et al.
Published: (2025-02-01) -
Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study
by: M. Doyinsola Bailey, et al.
Published: (2025-12-01) -
Health care resource use and costs associated with adult pneumococcal disease in the United States from 2017 to 2019, stratified by age and health risk: a retrospective cohort study
by: Nicole Cossrow, et al.
Published: (2025-07-01) -
Efficacy of conjugate vaccines in pneumococcal infection prevention
by: A. L. Perova, et al.
Published: (2014-09-01) -
What do Patients Know About Pneumococcal Vaccine?
by: Fatma Çiftci, et al.
Published: (2017-08-01)